Who Buys Everolimus from India — 135 Importers Behind a $37.9M Market
India's everolimus import market is served by 135 active buyers who collectively imported $37.9M across 620 shipments. ASCEND GMBH (GERMANY) leads with a 15.7% market share, followed by ASCEND LABORATORIES LLC and BRECKENRIDGE PHARMACEUTICAL INC. The top 5 buyers together control 55.9% of total import value, reflecting a moderately competitive buyer landscape.
Top Everolimus Importers — Ranked by Import Value
ASCEND GMBH (GERMANY) is the leading everolimus importer from India, holding a 15.7% share of the $37.9M market across 620 shipments from 135 buyers. The top 5 buyers — ASCEND GMBH (GERMANY), ASCEND LABORATORIES LLC (UNITED STATES), BRECKENRIDGE PHARMACEUTICAL INC (UNITED STATES), PHARMACARE PREMIUM (MALTA), ASCEND LABORATORIES,LLC (UNITED STATES) — collectively control 55.9% of total import value.
Top Everolimus Buyers & Importers
Ranked by import value · 135 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | ASCEND GMBHGERMANY EVEROLIMUS ASCEND 1MG TABLETS [1275 X 10X10'S]EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USA | $6.0M | 5 | 15.7% |
| 2 | ASCEND LABORATORIES LLCUNITED STATES EVEROLIMUS ASCEND 1MG TABLETS [1275 X 10X10'S]EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USA | $4.5M | 5 | 12.0% |
| 3 | BRECKENRIDGE PHARMACEUTICAL INCUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $4.2M | 5 | 11.0% |
| 4 | PHARMACARE PREMIUMMALTA EVEROLIMUS TABLETS 10 MGEVEROLIMUS 10 MG TABLETS CI NO:124045)EVEROLIMUS TABELTS 10 MG (OTHER R | $3.9M | 5 | 10.4% |
| 5 | ASCEND LABORATORIES,LLCUNITED STATES EVEROLIMUS ASCEND 1MG TABLETS [1275 X 10X10'S]EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USA | $2.6M | 5 | 6.8% |
| 6 | BOSTON ONCOLOGY ARABIASAUDI ARABIA EVEROLIMUS 5MG TABLET OUR REF CI NO:124265)EVEROLIMUS 5MG TABLETSEVEROLIMUS 10MG TABLET OUR REF CI NO:124265) | $2.6M | 5 | 6.8% |
| 7 | BRECKENRIDGE PHARMACEUTICALS INCUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $1.9M | 5 | 5.0% |
| 8 | BRECKENRIDGE PHARMACEUTICAL, INCUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $1.5M | 5 | 4.0% |
| 9 | NATCOFARMA DO BRASIL LTDA,BRAZIL EVEROLIMUS 10MG TABLETS 28'S (OTHER REFE | $1.3M | 5 | 3.3% |
| 10 | BIOCON PHARMA INCUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $1.1M | 5 | 3.0% |
| 11 | BRECKENRIDGE PHARMACEUTICALUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $1.1M | 5 | 2.9% |
| 12 | NATCOFARMA DO BRASIL LIMITEDABRAZIL EVEROLIMUS 10MG TABLETS 28'S (OTHER REFE | $888.7K | 5 | 2.3% |
| 13 | XXOCOXXPHAXXA IXXUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $653.6K | 5 | 1.7% |
| 14 | BRECKENRIDGEPHARMACEUTICAL INCUNITED STATES EVEROLIMUS TABLETS 0.5 MG [3264 PACK X 6 X 10'S] (EVEROLIMUS TABLETS 10MG 30#S BOTTLE USAEVEROLIMUS TABLETS 10MG | $559.4K | 5 | 1.5% |
| 15 | NATCO FARMA DO BRASIL LTDABRAZIL EVEROLIMUS 10MG TABLETS 28'S (OTHER REFE | $555.8K | 5 | 1.5% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Everolimus — and from which countries?
Flow of Everolimus exports from India: each country's share and the named importers behind the numbers
Everolimus — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $19.1M through 211 shipments. This represents a market share of 50.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• ASCEND LABORATORIES LLC - $4.5M (23.8% of country's total business)
• BRECKENRIDGE PHARMACEUTICAL INC - $4.2M (21.7% of country's total business)
• ASCEND LABORATORIES,LLC - $2.6M (13.5% of country's total business)
• BRECKENRIDGE PHARMACEUTICALS INC - $1.9M (9.9% of country's total business)
• BRECKENRIDGE PHARMACEUTICAL, INC - $1.5M (7.8% of country's total business)
• Rest of United States's importers - $4.4M (23.2% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $90.7K, indicating premium pricing strategy compared to the market average of $61.1K.
United States is a key market for Everolimus imports, representing 50.5% of total trade value.
2Germany
Germany emerges as the second largest importing country, achieving a total trade value of $6.0M through 27 shipments. This represents a market share of 15.7% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Germany has a diverse importer base, with their top importers including:
• ASCEND GMBH - $6.0M (100.0% of country's total business)
Key Insight: Germany demonstrates strong market positioning with an average shipment value of $220.7K, indicating premium pricing strategy compared to the market average of $61.1K.
Germany is a key market for Everolimus imports, representing 15.7% of total trade value.
3Malta
Malta emerges as the third largest importing country, achieving a total trade value of $3.9M through 45 shipments. This represents a market share of 10.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Malta has a diverse importer base, with their top importers including:
• PHARMACARE PREMIUM - $3.9M (100.0% of country's total business)
Key Insight: Malta demonstrates strong market positioning with an average shipment value of $87.4K, indicating premium pricing strategy compared to the market average of $61.1K.
Malta is a key market for Everolimus imports, representing 10.4% of total trade value.
4Brazil
Brazil emerges as the fourth largest importing country, achieving a total trade value of $3.1M through 17 shipments. This represents a market share of 8.3% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Brazil has a diverse importer base, with their top importers including:
• NATCOFARMA DO BRASIL LTDA, - $1.3M (40.3% of country's total business)
• NATCOFARMA DO BRASIL LIMITEDA - $888.7K (28.3% of country's total business)
• NATCO FARMA DO BRASIL LTDA - $555.8K (17.7% of country's total business)
Key Insight: Brazil demonstrates strong market positioning with an average shipment value of $184.5K, indicating premium pricing strategy compared to the market average of $61.1K.
Brazil is a key market for Everolimus imports, representing 8.3% of total trade value.
5Saudi Arabia
Saudi Arabia emerges as the fifth largest importing country, achieving a total trade value of $2.6M through 6 shipments. This represents a market share of 6.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Saudi Arabia has a diverse importer base, with their top importers including:
• BOSTON ONCOLOGY ARABIA - $2.6M (99.7% of country's total business)
Key Insight: Saudi Arabia demonstrates strong market positioning with an average shipment value of $429.8K, indicating premium pricing strategy compared to the market average of $61.1K.
Saudi Arabia is a key market for Everolimus imports, representing 6.8% of total trade value.
Buyer Segment Analysis
TransData Nexus Everolimus buyer market intelligence
1Buyer Segment Analysis
The importation of Everolimus from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like ASCEND GMBH (Germany) and ASCEND LABORATORIES LLC (United States) function as intermediaries, procuring Everolimus in bulk to supply to healthcare providers and pharmacies. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.
- Contract Manufacturers: Companies such as BIOCON PHARMA INC (United States) and NATCOFARMA DO BRASIL LTDA (Brazil) import Everolimus for formulation and packaging under specific contracts. Their procurement is project-based, aligning with production schedules and client demands.
- Re-exporters: Entities like PHARMACARE PREMIUM (Malta) and BOSTON ONCOLOGY ARABIA (Saudi Arabia) import Everolimus with the intent to re-export to other markets. Their purchasing behavior is influenced by global demand fluctuations and regulatory considerations in target markets.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Everolimus buyer market intelligence
1Country-Specific Import Regulations
Importing Everolimus into the top five importing countries involves navigating specific regulatory frameworks:
- United States:
- Regulatory Authority: Food and Drug Administration (FDA).
- Import Registration Process: Requires submission of an Abbreviated New Drug Application (ANDA) for generic drugs, including comprehensive data on bioequivalence and manufacturing practices.
- Estimated Timeline: Typically 10-12 months, subject to FDA review processes.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally duty-free.
- Germany:
- Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
- Import Registration Process: Requires a Marketing Authorization Application (MAA) submission, including quality, safety, and efficacy data.
- Estimated Timeline: Approximately 7-12 months, depending on the completeness of the application.
- Import Tariff/Duty: As an EU member, Germany applies a 0% tariff on pharmaceutical products under HS Code 30049049.
- Malta:
- Regulatory Authority: Malta Medicines Authority (MMA).
- Import Registration Process: Submission of a Marketing Authorization Application, aligned with EU directives.
- Estimated Timeline: Approximately 6-9 months.
- Import Tariff/Duty: As part of the EU, Malta imposes a 0% tariff on pharmaceutical imports under HS Code 30049049.
- Brazil:
- Regulatory Authority: National Health Surveillance Agency (ANVISA).
- Import Registration Process: Requires submission of a Dossier for Registration of Medicines, including clinical data and manufacturing details.
- Estimated Timeline: Typically 12-18 months, subject to ANVISA's review process.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are subject to a 14% import duty.
- Saudi Arabia:
- Regulatory Authority: Saudi Food and Drug Authority (SFDA).
- Import Registration Process: Submission of a Drug Registration Application, including comprehensive quality and clinical data.
- Estimated Timeline: Approximately 12-14 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally exempt from import duties.
Navigating these regulatory landscapes requires meticulous planning and adherence to each country's specific requirements to ensure successful market entry.
Demand Drivers & Market Opportunity
TransData Nexus Everolimus buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Everolimus across importing countries is driven by several key factors:
- Disease Prevalence: Everolimus is primarily used in oncology and transplant medicine. The global rise in cancer incidence, with nearly 10 million deaths annually as of 2025, underscores the increasing need for effective treatments. (who.int)
- Government Healthcare Programs: Many countries have implemented programs to enhance access to essential medicines. For instance, over 150 countries have adopted national essential medicines lists based on the WHO Model List, facilitating procurement and distribution of critical drugs like Everolimus. (who.int)
- Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased availability and affordability of essential medicines. The WHO's inclusion of new cancer treatments in its Essential Medicines List in 2025 reflects a commitment to expanding access to life-saving therapies. (who.int)
- WHO Essential Medicines List Procurement: The inclusion of Everolimus in the WHO Model List of Essential Medicines facilitates its procurement by member states, ensuring broader access. (who.int)
- Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through tender systems, ensuring competitive pricing and consistent supply. The presence of 135 buyers across 67 countries indicates a robust and diverse market for Everolimus, highlighting significant opportunities for suppliers.
These factors collectively contribute to a growing market for Everolimus, presenting substantial opportunities for suppliers to meet the increasing global demand.
Common Questions — Everolimus Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest everolimus buyer importing from India?
Based on import volume and value, ASCEND GMBH (GERMANY) leads with $6.0M in imports and a 15.7% market share — the highest of any single everolimus importer. ASCEND LABORATORIES LLC (UNITED STATES) and BRECKENRIDGE PHARMACEUTICAL INC (UNITED STATES) are the next largest buyers.
QHow many companies buy everolimus from India?
There are 135 active everolimus buyers importing from India, with a combined market of $37.9M across 620 shipments to 67 countries. The top 5 buyers hold 55.9% of total import value, while the remaining 130 buyers handle the other 44.1%.
QWhich countries import the most everolimus from India?
The top importing countries for everolimus from India are United States (50.5%), Germany (15.7%), Malta (10.4%), Brazil (8.3%), Saudi Arabia (6.8%). These markets represent the largest demand centres for Indian pharmaceutical exports of everolimus, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for everolimus from India?
The average import transaction value for everolimus from India is $61.1K, with an average unit price of $82.98 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Everolimus buyer market intelligence
1Buyer Segment Analysis
The importation of Everolimus from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like ASCEND GMBH (Germany) and ASCEND LABORATORIES LLC (United States) function as intermediaries, procuring Everolimus in bulk to supply to healthcare providers and pharmacies. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.
- Contract Manufacturers: Companies such as BIOCON PHARMA INC (United States) and NATCOFARMA DO BRASIL LTDA (Brazil) import Everolimus for formulation and packaging under specific contracts. Their procurement is project-based, aligning with production schedules and client demands.
- Re-exporters: Entities like PHARMACARE PREMIUM (Malta) and BOSTON ONCOLOGY ARABIA (Saudi Arabia) import Everolimus with the intent to re-export to other markets. Their purchasing behavior is influenced by global demand fluctuations and regulatory considerations in target markets.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Everolimus buyer market intelligence
1Country-Specific Import Regulations
Importing Everolimus into the top five importing countries involves navigating specific regulatory frameworks:
- United States:
- Regulatory Authority: Food and Drug Administration (FDA).
- Import Registration Process: Requires submission of an Abbreviated New Drug Application (ANDA) for generic drugs, including comprehensive data on bioequivalence and manufacturing practices.
- Estimated Timeline: Typically 10-12 months, subject to FDA review processes.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally duty-free.
- Germany:
- Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
- Import Registration Process: Requires a Marketing Authorization Application (MAA) submission, including quality, safety, and efficacy data.
- Estimated Timeline: Approximately 7-12 months, depending on the completeness of the application.
- Import Tariff/Duty: As an EU member, Germany applies a 0% tariff on pharmaceutical products under HS Code 30049049.
- Malta:
- Regulatory Authority: Malta Medicines Authority (MMA).
- Import Registration Process: Submission of a Marketing Authorization Application, aligned with EU directives.
- Estimated Timeline: Approximately 6-9 months.
- Import Tariff/Duty: As part of the EU, Malta imposes a 0% tariff on pharmaceutical imports under HS Code 30049049.
- Brazil:
- Regulatory Authority: National Health Surveillance Agency (ANVISA).
- Import Registration Process: Requires submission of a Dossier for Registration of Medicines, including clinical data and manufacturing details.
- Estimated Timeline: Typically 12-18 months, subject to ANVISA's review process.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are subject to a 14% import duty.
- Saudi Arabia:
- Regulatory Authority: Saudi Food and Drug Authority (SFDA).
- Import Registration Process: Submission of a Drug Registration Application, including comprehensive quality and clinical data.
- Estimated Timeline: Approximately 12-14 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally exempt from import duties.
Navigating these regulatory landscapes requires meticulous planning and adherence to each country's specific requirements to ensure successful market entry.
Demand Drivers & Market Opportunity
TransData Nexus Everolimus buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Everolimus across importing countries is driven by several key factors:
- Disease Prevalence: Everolimus is primarily used in oncology and transplant medicine. The global rise in cancer incidence, with nearly 10 million deaths annually as of 2025, underscores the increasing need for effective treatments. (who.int)
- Government Healthcare Programs: Many countries have implemented programs to enhance access to essential medicines. For instance, over 150 countries have adopted national essential medicines lists based on the WHO Model List, facilitating procurement and distribution of critical drugs like Everolimus. (who.int)
- Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased availability and affordability of essential medicines. The WHO's inclusion of new cancer treatments in its Essential Medicines List in 2025 reflects a commitment to expanding access to life-saving therapies. (who.int)
- WHO Essential Medicines List Procurement: The inclusion of Everolimus in the WHO Model List of Essential Medicines facilitates its procurement by member states, ensuring broader access. (who.int)
- Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through tender systems, ensuring competitive pricing and consistent supply. The presence of 135 buyers across 67 countries indicates a robust and diverse market for Everolimus, highlighting significant opportunities for suppliers.
These factors collectively contribute to a growing market for Everolimus, presenting substantial opportunities for suppliers to meet the increasing global demand.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 135 global importers of Everolimus identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 620 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 67 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
620 Verified Shipments
135 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists